Title: Inflammatory and JAK-STAT Pathways as Shared Molecular Targets for ANCA-Associated Vasculitis and Nephrotic Syndrome

Running title: Shared Inflammatory Pathways in ANCA-associated Vasculitis and Nephrotic Syndrome

Sean Eddy¹, Viji Nair¹, Laura H. Mariani¹, Felix H. Eichinger¹, John Hartman¹, Huateng Huang¹, Hemang Parikh², Jaclyn N. Taroni³, Maja T. Lindenmeyer^{4,5}, Wenjun Ju¹, Casey S. Greene³, Peter C. Grayson⁶, Brad Godfrey¹, Clemens D. Cohen⁴, Matt G. Sampson⁷, Richard A. Lafayette⁸, Nephrotic Syndrome Study Network (NEPTUNE), European Renal cDNA Bank – Else Kröner-Fresenius Biopsy Bank (ERCB), Vasculitis Clinical Research Consortium (VCRC), Jeffrey Krischer², Peter A. Merkel⁹, Matthias Kretzler^{1,10}

¹*Division of Nephrology, University of Michigan, Ann Arbor, MI, 48104, USA*

²*Health Informatics Institute, Morsani College of Medicine, University of South Florida, Tampa, FL, 33620, USA*

³*Department of Systems Pharmacology and Translational Therapeutics, Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, 19104, USA*

⁴*Nephrological Center Medical Clinic and Policlinic IV, University of Munich, Munich, Germany*

⁵*Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

⁶*Vasculitis Translational Research Program, NIAMS, NIH, Bethesda, MD, 20892, USA*

⁷*Department of Pediatrics-Nephrology; University of Michigan School of Medicine, Ann Arbor, MI, 48104, USA*

⁸*Division of Nephrology and Hypertension, Stanford University Medical Center, Sanford, CA, 94305, USA*

⁹*Division of Rheumatology and Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, 19104, USA*

¹⁰*Department of Computational Medicine and Bioinformatics, University of Michigan School of Medicine, Ann Arbor, MI, 48104, USA*

Corresponding Author:

Matthias Kretzler MD

Nephrology/Internal Medicine and Computational Medicine and Bioinformatics

University of Michigan

1150 W. Medical Center Dr.-SPC5676

Ann Arbor, MI 48109-5676

734-615-5757, fax: 734-763-0982

E-MAIL: kretzler@umich.edu

Word Count:

Abstract: 249 words

ABSTRACT

Background: Glomerular diseases of the kidney are presently differentiated, diagnosed and treated according to conventional clinical or structural features. While etiologically diverse, these diseases share common clinical features including but not limited to reduced glomerular filtration rate, increased serum creatinine and proteinuria suggesting shared pathogenic mechanisms across diseases. Renal biopsies from patients with nephrotic syndrome (NS) or ANCA-associated vasculitis (AAV) were evaluated for molecular signals cutting across conventional disease categories as candidates for therapeutic targets.

Methods: Renal biopsies were obtained from patients with NS (minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy) (n=187) or AAV (granulomatosis with polyangiitis or microscopic polyangiitis) (n=80) from the Nephrotic Syndrome Study Network (NEPTUNE) and the European Renal cDNA Bank. Transcriptional profiles were assessed for shared disease mechanisms.

Results: In the discovery cohort, 10-25% transcripts were differentially regulated versus healthy controls in both NS and AAV, >500 transcripts were shared across diseases. The majority of shared transcripts (60-77%) were validated in independent samples. Therapeutically targetable networks were identified, including inflammatory JAK-STAT signaling. *STAT1* eQTLs were identified and *STAT1* expression associated with GFR-based outcome. A transcriptional *STAT1* activity score was generated from *STAT1*-regulated target genes which correlated with *CXCL10* (p<0.001), a JAK-STAT biomarker, predictors of CKD progression, interstitial fibrosis (r=0.41, p<0.001), and urinary EGF (r=-0.51, p<0.001).

Conclusion: AAV and NS caused from histopathologically distinct disease categories share common intra-renal molecular pathways cutting across conventional disease classifications. This approach provides a starting point for de novo drug development, and repurposing efforts in rare kidney diseases.

Introduction

Rare diseases represent a unique challenge in both patient management and drug development. Nearly 30 million Americans, or approximately 10% of the population, are afflicted by at least one of over 7,000 rare diseases^{1,2}. Because the patient population for any single rare disease cause can be quite small, understanding the underlying mechanisms of each disease and thus, the opportunity to develop and apply effective treatments is limited. As a consequence, the majority of rare diseases have no approved therapies^{1,3}. With the advance of molecular profiling of tissue samples obtained from organ systems damaged by the rare disease, a data-driven understanding of the molecular basis across these diseases is in reach. Understanding shared molecular pathways activated during tissue damage can help broadly define mechanisms in distinct diseases that may be leveraged for drug discovery and repurposing across rare diseases⁴. By selectively targeting specific mechanisms of rare diseases responsible for chronic progressive end-organ dysfunction and damage, it may be possible to preserve organ function even when the disease initiating process is not directly impacted.

Nephrotic syndrome (NS) refers to a group of symptoms resulting from etiologically distinct diseases including focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN). To address the opportunity for drug repurposing and target identification in rare renal diseases, histologically distinct rare diseases (primary nephrotic syndrome (NS) and ANCA-associated vasculitis (AAV, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)) that each can result in end-organ kidney damage, were evaluated to identify shared molecular targets. Based on previous work that identified shared pathways across many distinct histopathologically defined chronic kidney diseases including primary forms of NS: FSGS, MCD and MN, as well as diabetic kidney disease and lupus nephritis⁵, the hypothesis tested was that transcriptional profiling in etiologically distinct rare diseases would enable the identification of shared disease mechanisms. Using primary NS (FSGS, MCD, and MN) and AAV as exemplar disease indications, we sought to test this hypothesis. These profiles were subsequently interrogated to identify shared activated

pathways, with a focus on inflammation and fibrosis, and subsequently linked to clinical features and non-invasive biomarkers of pathway activation (Figure 1). Activated pathways were further evaluated to discover opportunities for drug repurposing, and identification of novel drug targets and/or biomarkers of kidney disease (Figure 1).

Results

Previous studies have indicated shared networks in FSGS, MCD, and MN⁵; and current studies from our group have demonstrated a continuum of expression between FSGS and MCD (unpublished data), we first sought to confirm common transcriptional programs in these primary forms of NS using data reduction and data-driven approach to assess transcriptional profiles from subjects with FSGS, MCD, or MN. Using transcriptional data generated from subjects with FSGS, MCD, and MN from ERCB, there were no distinct disease-specific clusters when a principal component analysis was performed on both the glomeruli or tubulointerstitium compartments (using data deposited in GEO under GSE104948 and GSE104954, Supplemental Figure 1a and 1b). To assess this statistically, eigen vectors for the first three principal components were assessed for differences across histopathologically classified diseases and displayed no evidence of significant differences (Supplemental Figure 1c-e), thus FSGS, MCD, and MN were considered as a group of primary NS for comparison with AAV. To identify shared molecular mechanisms in NS and AAV (Figure 1), intrarenal transcripts in NS and AAV were evaluated in a discovery set from the ERCB. Affymetrix GeneChip-based steady state transcript expression from the kidney was separately derived from the glomeruli and tubulointerstitial compartment of kidney biopsies from 62 patients with NS and 23 patients with AAV from the ERCB (Table 1, Discovery cohort) and compared to intrarenal transcript profiles generated from 22 healthy living transplant donor biopsies (LD). In the tubulointerstitium, 1768 of the total of 11,666 expressed transcripts assessed in samples from patients with AAV and 565 genes in samples from patients with NS were differentially expressed ($|FC| > 1.3$, $q\text{-value} < 0.05$) versus LD. Of the 565 differentially expressed transcripts in the tubulointerstitium from subjects with NS, 90% (511/565) were also differentially expressed in the tubulointerstitium from subjects with AAV (Figure 2a). Importantly, the direction of expression was conserved across all transcripts in the tubulointerstitium, with a heatmap of the differentially expressed genes in the discovery cohort shown in Figure 2b. The top 10 differentially expressed transcripts in the tubulointerstitium from the discovery cohort are shown in Table 2, while a full list of differentially expressed transcripts is provided in Supplemental Table 1. In the glomeruli, 2322 genes were differentially expressed in AAV relative to LD, and 1059 in NS versus LD

biopsies. A majority of differentially expressed transcripts in the glomeruli from patients with NS, (88% or 930/1059) were also differentially expressed in the glomeruli from patients with AAV, and nearly all (99.8% or 928/930) of shared transcripts were regulated in the same direction across diseases (Supplemental Figure 2, differentially expressed transcripts in the glomerular compartment are provided in Supplemental Table 2). These results are consistent with a common shared intra-renal transcriptional response across kidney diseases, independent of histopathological diagnosis.

Hierarchical clustering was then performed on the differentially expressed genes in the discovery cohort to explore sample and cluster level similarities or differences in expression profiles from patients with nephrotic syndrome and ANCA-associated vasculitis. Using the tubulointerstitial data, hierarchical clustering identified four clusters (Figure 3a). The first cluster contained all of the healthy LD samples, as well as a broad spectrum of samples across kidney diseases (MCD, FSGS, AAV), while clusters 2, 3, and 4 contained samples from all diseases, but no LD (Figure 3b). The association of transcript clusters with phenotypes was evaluated by assessing eGFR across the clusters (Figure 3c). Within each histological diagnosis, significant eGFR differences were observed across clusters (ANOVA, $p < 0.05$) (Figure 3c). The majority of transcriptional profiles from MCD patient samples were found in clusters 1 and 2 and these were from patients with MCD that had the highest mean eGFR (110 ± 20 and 82 ± 35 in clusters 1 and 2, respectively). Conversely, a majority of profiles from AAV patient samples were found in clusters 3 and 4 (Figure 3b), and were from patients with the lowest eGFR across AAV (14 ± 10 and 15 ± 10 for clusters 3 and 4 respectively). Samples from patients within each histological diagnosis, had significantly lower eGFR in cluster 4 ($p < 0.001$), and increased transcripts in this cluster of patients were negatively correlated with log2 eGFR across diseases. For example, the top differentially regulated genes in cluster 4 - *CXCL6*, *C3* and *SERPINA3* showed a negative GFR correlation ($r \leq -0.4$, $p < 0.001$ for all three genes, Figure 3d) linking an inflammatory disease state to impaired renal function independent of underlying histological diagnosis.

To validate shared transcripts in the tubulointerstitium and glomeruli, we profiled an independent set of samples for AAV from ERCB and an independent set of samples for nephrotic syndrome from NEPTUNE on Affymetrix ST2.1 gene chips (Table 1, Validation cohort), assessing the 511 shared transcripts identified in the tubulointerstitium and the 928 shared transcripts in the glomeruli from the discovery set (Table 3). In the tubulointerstitium, 508 of 511 genes identified in the discovery cohort were expressed above background expression levels in the validation cohort and could be assessed for differential expression, while all 928 differentially expressed genes in the glomeruli were available for assessment in the validation cohort. Table 3 provides summary level information and individual genes validated in both the tubulointerstitium and glomeruli; full results are provided in Supplemental Tables 3 and 4 for each compartment, respectively. Thus, the vast majority of transcripts identified as differentially regulated and shared between diseases in the discovery phase were validated in a test dataset of independent samples.

The complement gene, *C3* was among the highest up-regulated transcript in both tubulointerstitial and glomerular samples from patients with NS and AAV in the discovery and validation cohorts (Figure 4a-d). As complement activation has been implicated in AAV⁶, the status of the pathway in AAV and NS was investigated further. Multiple genes in the complement pathway showed tissue level transcript up-regulation in both NS and AAV in the TI (Figure 4e). The complement system pathway was one of the most significantly increased canonical pathways as tested by a panel of enrichment strategies (Table 4).

While individual gene expression profiles can be identified and mapped as drug targets, identifying the upstream mechanisms influencing downstream gene expression is likely a more rigorous strategy to identify functionally active, and potentially targetable signaling networks⁷⁻⁹. To derive the activation state of targetable pathways from the transcriptional profiles, two approaches were taken. The first strategy assessed whether any of the validated differentially expressed transcripts (396 shared transcripts with q-value<0.1 in the tubulointerstitium) could be explained by predicted upstream regulators. This was paired with an independent

approach to match the shared transcriptional profile with those of cell lines exposed to various perturbagens targeting known pathways (small molecules, over-expressing constructs, and siRNA knockdown).

Upstream regulators are molecules (including but not limited to: transcription factors, growth factors, kinases, chemicals) predicted to affect activity of downstream expression profiles. Activities are predicted using literature derived cause and effect relationships, e.g. up-regulation of a transcription factor target gene supports a predicted activation in the transcription factor, while down-regulation supports inhibition⁷⁻⁹. The top biological networks from upstream regulator analysis in the TI are shown in Table 5 (an expanded list of results is provided in Supplemental Table 5; glomerular results are found in Supplemental Table 6). Predicted activities of upstream regulators are based on directionality of underlying gene expression that is similar to (predicted activation) or inverse (predicted inhibition) of the uploaded differential expression signature. The top enriched upstream regulators were indicative of inflammatory pathway activation, and included predicted activation of cytokines IFN γ , TNF and predicted inhibition of the glucocorticoid receptor (NR3C1). A mechanistic network of interconnected upstream regulators was discovered (upstream regulators that can explain multiple downstream transcripts as part of a network) (Figure 5a), and explains 56% of the downstream gene expression changes in the shared, tubulointerstitial data set ((222/396)).

To further define functional associations, the 396 gene shared transcriptional profile from the tubulointerstitium was used to query Connectivity Map (CMap) L1000 profiles¹⁰. The resulting CMap output contains a ranking of experimentally generated transcriptional profiles generated in cell lines that are inverse (potential therapeutic) or similar (potentially exacerbating disease) to the shared transcriptional profile. This provided an additional, independent, data-driven approach to identify signaling networks and potential drug targets active in patients with NS and AAV. For these analyses, CMap profiles were limited to those with absolute profile scores >50 (13% of CMap profiles met this criteria). Looking at compound profiles that are inversely related to the shared signature, profiles of glucocorticoid agonists were the most frequent (Figure

5b). Calcium channel blockers were also identified. IKK inhibitors, which block NFκB activation were also identified as inversely related to the shared signature. Activation of NFκB and RELA (p65 subunit of NFκB) were also predicted as part of the shared transcriptional profile and are present in the upstream regulator network (Figure 5a). Interestingly, a number of profiles from ATPase inhibitors, HDAC inhibitors, protein synthesis inhibitors, and proteasome inhibitors were also identified. Over-expression (OE) experiments (Supplemental Table 7) with the highest CMap profile scores indicating a signature similar to the shared molecular profile included HLA-DRA (99.91), consistent with an inflammatory signal and PSMB10 (95.43), which would suggest elevated proteasome signaling shared across diseases.

To gain further insight into key signaling networks shared across diseases, upstream regulators with predicted activities from IPA were compared with CMap profiles to test for consensus between these two independent modeling approaches. The top 15 unique TI networks are shown in Table 6, (multiple CMap profiles for a compound are often observed due to profiles being generated for different treatment concentrations or duration) with 67% (10/15) showing consensus using independent approaches. These included networks representing lower glucocorticoid signaling (dexamethasone and fluticasone), reduced transcription factor activities in the TI of FOXA1 and HNF4A, and activation of CD44, STAT1, and SOX2 (Table 6). In CMap profiles, experimental knock-down of STAT1 resulted in an expression profile that was the inverse of the shared disease profile, and was among the top 5% of profiles showing this inverse relationship (Figure 5c). In the glomeruli, 18 unique nodes were identified (Supplemental Table 8) and 61% (11/18) were consistent across the two analyses. These included nodes representing a lowered glucocorticoid signal (dexamethasone), reduced transcription factor activities of FOXA1, HNF1A and HNF4A, and activation of TLR7, IL2, CCND1, PLAUR, IFNGR1, and NR0B2. These pathways are consistent with inflammatory activation and decreased epithelial differentiation states common among NS and AAV.

Consensus findings from IPA and CMap profiles were then investigated for the potential underlying genetic components that might contributed to an alteration in disease-associated expression and activity. TI and glomerular-specific *cis*-eQTLs were generated across the NEPTUNE cohort (www.nephqtl.org)¹¹; *cis*-eQTLs were fine mapped using the Bayesian Deterministic Approximation of Posteriors¹², which identifies clusters of variants predicted to drive eQTL associations. *STAT1*, *CD44*, *SOX2*, *FOXA1*, *ATP2A1*, *ATP2A2*, *ATP2A3* (the ATP2A family members encode sarcoplasmic reticulum Ca²⁺ ATPase and are targets of thapsigargin), *IPMK*, *HNF4A*, *MAPK1*, and *NR3C1* (translated protein is the glucocorticoid receptor, a target of prednisone and dexamethasone) were assessed in TI-specific eQTL analyses, and *TLR7*, *IL2*, *NROB2*, *PLAUR*, *IFNGR1*, *FLT3* (the translated protein is a target of sunitinib) *FOXA1*, *HNF4A*, *HNF1A*, and *NR3C1* were assessed in glomerular-specific multi-SNP eQTL analyses. Analyses of eQTLs for these genes in the TI and glomeruli only identified *STAT1* with a gene level FDR<0.05 (Supplemental Table 9. As variants associated with *STAT1* expression were non-coding, expression of *STAT1* was investigated for associations with outcome across the NEPTUNE cohort. Samples were binned in tertiles according to *STAT1* expression. In an unadjusted model, elevated *STAT1* expression was significantly associated with faster progression to a composite eGFR endpoint (time to ESRD or 40% loss of eGFR) (log rank p-value<0.01) (Figure 6).

Because expression of a single gene is not necessarily indicative of network or pathway activity, a *STAT1* score was generated, given that a similar approach yielded a JAK-STAT activation score that was associated with increased *STAT1* and *STAT3* phosphorylation in FSGS¹³. Using a data driven approach, a kidney-specific *STAT1* network comprised of 17 genes was identified¹⁴, and further refined for genes functionally up-regulated by IFN γ stimulation by utilizing the Database of IFN Regulated Genes, Interferome¹⁵. Transcripts were considered validated if they showed at least 2-fold increase by IFN γ stimulation in at least 5 datasets. Next, the genes were assessed for the presence of *STAT1* or *STAT* family binding sites, bringing the *STAT1* activated gene set to 14 genes (detailed in Supplemental Table 10). The *STAT1* activation score was strongly correlated with *STAT1* expression in the discovery ($r=0.95$, $p<0.001$, $n=68$) and validation cohorts ($r=0.89$, $p<0.001$) (data not shown).

IP-10 (CXCL10) has been used as a target engagement and renal inflammation biomarker in a clinical trial assessing the effectiveness of JAK inhibition in patients with diabetic kidney disease treated with baricitinib¹⁶, but was not used to generate the STAT1 activation score. The STAT1 activation score strongly correlated with *CXCL10* mRNA levels in both the discovery (Figure 7a, $r=0.81$, $p<0.001$, $n=68$) and validation (Figure 7b, $r=0.58$, $p<0.001$, $n=166$) AAV and NS datasets, as it did in DKD in confirmation of the clinical trial observation^{17,18} (Supplemental Figure 3). Because STAT1 activation can be considered a reflection of the intra-renal inflammatory state and has been reported to drive tissue fibrosis¹⁹, the interaction of the STAT1 activation score with interstitial fibrosis was assessed. In NEPTUNE NS patients, the STAT1 activation score was correlated with interstitial fibrosis (Figure 7c, $r=0.41$, $p<0.001$, $n=95$). Similar results were found associating STAT1 activation score with tubular atrophy (Supplemental Figure 4). Intrarenal epidermal growth factor (*EGF*) mRNA levels and urinary EGF to creatinine ratios (uEGF) have been identified as markers of tubular differentiation and regeneration. Indeed, renal tissue *EGF* mRNA and urinary EGF protein have been reported to negatively correlate with interstitial fibrosis and tubular atrophy, and can predict progression of CKD¹⁷. The STAT1 activation score significantly and inversely correlated with *EGF* mRNA in both the discovery and test datasets (Figure 7d, $r=-0.58$, $p<0.001$, $n=68$ and Figure 7e, $r=-0.57$, $p<0.001$, $n=166$), and uEGF (Figure 7f, $r=-0.51$, $p<0.001$, $n=62$). In each case the STAT1 activation score was negatively correlated with *EGF* and uEGF, supporting the link of inflammation, epithelial dysfunction, renal fibrosis and long term progression of glomerular disease.

Discussion

Parenchymal organs require high degrees of differentiation to perform their specialized functions. This differentiation, however, can limit cellular programs that are activated in response to a diverse set of injury mechanisms. Tissues require, at least in part, dedifferentiation to carry out cellular damage responses²⁰⁻²². Across many epithelial organs a uniform response consisting of loss of epithelial function, innate immune response activation, and activation of chronic fibrotic responses can be observed²³⁻²⁶. Through the evaluation of shared tissue injury mechanisms across diseases, pathways associated with progressive loss of organ function may be used to identify disease-modifying pathways and networks as therapeutic targets capable of impacting patient care in multiple rare diseases. In the setting of the NIH Rare Clinical Disease Research Network this hypothesis was tested by mapping the transcriptional profiles of different diseases that cause kidney damage.

Consistent with previous findings of shared kidney-specific transcriptional mechanisms among patients with chronic kidney disease from various causes, in particular a strong transcriptional overlap in found in patients with diabetic nephropathy, lupus nephritis, and IgA nephropathy⁵, an analysis of samples from patients with diverse causes of primary NS or AAV yielded a large number of shared transcripts and mechanisms that were shared across conventional histological disease classifications. The majority of transcripts differentially expressed in NS (90%) were also found to be differentially expressed in AAV, were directionally consistent, and were validated in an independent set of patient samples. Of note, multiple genes in the classical and alternative complement pathway were among the shared altered transcripts in AAV and NS, in both the TI and glomeruli. Given the role that the alternative complement pathway plays in the kidney of patients with AAV⁶, Phase II trials suggesting the efficacy of alternate complement activation in patients with AAV through inhibition of C5a²⁷, and the heterogeneous C3 mRNA expression upstream of the alternative pathway, expanded targeting of complement activation in patients with other kidney diseases may be warranted.

Using the validated gene set for further analyses, a convergence of molecular mechanisms was identified including activation of inflammatory pathways and suppression or inhibition of differentiation related pathways. For the inflammatory-related pathways, evidence for their potential causal role in autoimmune or renal disease has been established, including TNF²⁸⁻³⁰, JAK-STAT¹⁶, NFκB³¹, proteasome signaling^{32,33}, and re-activation of glucocorticoid signaling through the use of glucocorticoid agonists³⁴. JAK-STAT pathway activation has already been implicated across other kidney diseases including diabetic kidney disease (DKD)³⁵⁻³⁸, and FSGS¹³. In addition to the inflammatory-related pathways, reduced HNF4 transcriptional activity could represent a state of de-differentiation as Hnf4a can induce mesenchymal to epithelial transition³⁹. Hnf4a co-expressed with Emx2, Hnf1b, and Pax8 has been shown to induce tubular epithelial cell differentiation⁴⁰. Furthermore, HNF4A was identified as a hub protein in a protein-protein interaction network of CKDGen genes with eGFR-associated expression, suggesting that reactivation of the HNF4A transcriptional program could have broad implications across CKD⁵.

Expertly curated causal inference associations, pathway enrichment, and experimentally-derived computational approaches to identify perturbations associated with a shared transcriptional profile in NS and AAV all converge on transcriptional mechanisms related to inflammatory and immune signaling, JAK-STAT, complement activation, and HNF4A. An assessment of convergent mechanism in the compartment specific eQTL landscape in kidney disease was performed across the NEPTUNE cohort. This analysis identified clusters of non-coding snps that were associated with *STAT1* expression in the tubulointerstitium, and elevated *STAT1* expression was associated with faster progression to a composite eGFR endpoint (40% loss of eGFR or ESRD).

Because transcription factor activation is driven by its ability to activate downstream transcription and not simply expression, we generated a STAT1 activation score. This approach was previously used to characterize JAK-STAT pathway activation and correlated with activated (phos-STAT) activation in FSGS¹³ in the NEPTUNE cohort. The STAT1 score correlated across diseases on an individual patient level with *CXCL10* (IP-10) mRNA,

and urinary EGF. IP-10 has been used as a pharmacodynamic biomarker in a Phase II trial suggesting the efficacy of baricitinib, an inhibitor of JAK1 and JAK2, in diabetic kidney disease³⁵. Given the successful phase II trial of baricitinib in DKD, the similarity of the STAT1 score in AAV relative to DKD, and the superiority of baricitinib compared to TNF inhibition in a distinct systemic autoimmune disease, rheumatoid arthritis⁴¹, argues for clinical evaluation of JAK inhibitors in patients with AAV. In addition, the similar level of signaling identified in NS, along with activation being associated with a progression biomarker, lends support to developing baricitinib for treatment of NS as well. Using a biomarker-driven approach in a precision medicine strategy, patients with active JAK-STAT signaling regardless of histological diagnosis could potentially benefit from targeted inhibition of the pathway using a basket clinical trial design⁴². The FDA recently approved the first treatment for cancer that applies a common biomarker to guide decisions about therapy, cutting across solid tumors as opposed to approval based on histological assessment of tumor origin.⁴³

This work establishes the landscape of underlying molecular mechanisms shared between nephrotic syndrome and ANCA-associated vasculitis. In a more general sense, identifying common disease mechanisms shared across rare diseases is an approach that may expand the currently limited treatment options. This may help to overcome limits in the molecular understanding of rare diseases, identify novel and known targetable mechanisms shared across diseases, and use the knowledge towards therapeutic repurposing for available drugs, ultimately improving treatment options for patients.

Methods

Patient cohorts

For the discovery cohort, samples from adult patients with AAV (n=23) and NS (n=62) were used from the European Renal cDNA Bank (ERCB). ERCB is a European multicenter study that collected renal biopsy tissue for gene expression analysis in RNA fixative (RNAlater, Qiagen), coupled with cross-sectional clinical information collected at the time of a clinically indicated renal biopsy⁴⁴. For the validation cohort, samples from adult patients with AAV (n=57) were obtained from the ERCB, and samples and clinical data from adult patients with NS (n=116) were obtained from the Nephrotic Syndrome Study Network (NEPTUNE). NEPTUNE is part of the National Institutes of Health Rare Disease Clinical Research Network (NIH RDCRN), and is a multicenter prospective cohort study that, at the time of this study, had enrolled patients with proteinuric glomerular disease and performed comprehensive clinical and molecular phenotyping at 23 sites. Patients with secondary glomerular disease (such as diabetic kidney disease, lupus nephritis, and amyloidosis) were excluded. The overall study design has been previously published⁴⁵. Comparable healthy renal tissue was obtained from living transplant donors (LD, n=29) and included in the study. Biopsy material from samples was microdissected into glomerular and tubulointerstitial compartments prior to transcriptional profiling as previously described⁴⁶.

Transcriptional profiling

Kidney tissue was processed as previously described⁴⁶. Briefly, renal biopsy tissue was stored in RNAlater® (ThermoFisher, Waltham, MA), and manually microdissected into tubulointerstitial and glomerular compartments. Microdissected renal biopsy specimens were processed and analyzed using Affymetrix GeneChip Human Genome U133A 2.0, U133 Plus 2.0 and Human Gene ST 2.1 Array platforms. Probe sets were annotated to Entrez Gene IDs using custom CDF version 19 generated from the university of Michigan Brain Array group⁴⁷. For the analysis of samples profiled on the U33A 2.0 and U133 Plus 2.0 platforms, we restricted the analysis to the non-Affx probe sets common to both platforms (12,074). Expression data was quantile

normalized and batch corrected using COMBAT⁴⁸. Technical replicates of human reference RNA profiles (Stratagene, La Jolla, CA) were included with each batch and used to assess batch correction efficiency. Differential gene expression across the transcriptome was compared between patients with NS and AAV versus living donors using the SAM method⁴⁹ in MEV (version 4.9); genes were defined as differentially expressed with $q\text{-value} < 0.05$ and fold-change thresholds were applied as defined in the manuscript. Hierarchical clustering analysis (Ward's method) was performed in Spotfire using Z-score normalized transcript expression. CEL files and processed data used in these analyses are accessible in GEO⁵⁰ under reference numbers: GSE104948, GSE104954, GSE108109, and GSE108112.

Functional enrichment and network analysis

Functional networks were interrogated for common disease mechanisms and upstream regulators, shared between both diseases using: QIAGEN's Ingenuity Pathways Analysis (IPA) (QIAGEN, Redwood City, CA, <https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis>). Automated assessment of literature curated cause and effect relationships was used to identify potential regulators of the shared transcriptional profile⁹. The approach derives a prediction of activation or inhibition by identifying potential network changes that can explain the observed gene expression profile (activated), or reverse the observed expression profile (inhibited). Genomatix Genome Analyzer (GGA)⁵¹ was used to identify pathway enrichment, and the Connectivity Map (CMap)^{10,52} and the Library of Network-Based Cellular Signatures (LINCS) Unified Environment (CLUE, <http://clue.io>) data version 1.0.1.1 was used to identify potential therapeutic targets through drug response signatures, and gene overexpression/knockdown signatures. At the time of analysis, LINCS contained cell line transcriptional responses to 8,878 perturbagens.

Development of STAT1 activation gene networks and activation scores

The STAT1 activation network was generated by first developing a kidney specific STAT1 interaction network using GIANT¹⁴ (minimum relationship confidence of 0.70, maximal network size of 20 genes), which resulted

in a 17 gene interaction network. To further refine the network, genes were assessed for functional activation in response to IFN-gamma stimulation using the Interferome database⁵³, and for the presence of STAT1 and STAT family binding sites in promoter regions, resulting in a 14 gene set representing STAT1 activation. The STAT1 activation score was generated in patient samples by transforming log2 expression profiles into Z-scores, and averaging Z-scores of 14-STAT1 dependent genes to generate a STAT1 activation score for each patient sample.

GFR estimates

GFR was estimated by the four-variable Modification of Diet in Renal Disease (MDRD) study equation⁵⁴ for each patient in ERCB and NEPTUNE.

Measurement of urinary EGF

uEGF concentration was measured in spot urine samples using the Human EGF Immunoassay Quantikine ELISA (R&D Systems) as previously described¹⁷.

Assessment of interstitial fibrosis and tubular atrophy

Histopathology was assessed in the NEPTUNE biopsy cohort with digital images obtained from paraffin-embedded kidney tissue stained with hematoxylin and eosin, PAS, silver-based, and trichrome stains⁵⁵. Whole slide images of glass slides from cases stored in the NEPTUNE digital pathology repository were assessed for percentage of cortex involved by IF/TA by six pathologists. The percentage of cortex involved by IF/TA was determined in each individual stain and averaged for an overall % value⁵⁶. Cases with paired tubulointerstitial gene expression were assessed.

Statistical analyses

Correlation analyses were performed using Pearson's correlation within Spotfire (TIBCO). Analysis of variance (ANOVA) was used to compare PC1, PC2, and PC3 eigenvalues across FSGS, MCD, and MN in the ERCB cohort, and to assess eGFR differences across patient clusters within Spotfire (TIBCO). A two-tailed unpaired t-test (unequal variance) was used to compare eGFR differences between clusters 1 and 4.

Author contributions

SE planned and analyzed human transcriptome data, database investigation, and correlation with clinical parameters, supervised JH, managed the project, critically reviewed data, and wrote the manuscript. VN provided critical experimental design suggestions. LM reviewed local pathology reports, and performed STAT1 outcome analysis in the NEPTUNE cohort. FE and HH performed NEPTUNE transcriptomic dataset normalization. JH contributed insight to STAT1 score development. MTL and CDC managed and provided samples from the ERCB. WJ analyzed urine EGF data. BG performed renal biopsy microdissection to obtain glomerular and tubulointerstitial compartments. HP, CSG, and JNT provided regular feedback for network defining approaches. PG provided expertise on ANCA-associated vasculitis and questions of relevance for clinicians treated patients with vasculitis. MGS provided an interpretation of eQTL results. RAL provided critical feedback on informatics approaches and expertise of JAK-STAT signaling in nephrotic syndrome. JK, PAM, and MK critically reviewed data and manuscript, and supervised the entire project. All authors contributed to and reviewed the manuscript.

Acknowledgements

Thanks and appreciation goes to the patients who consented for their biosamples to be used in this research. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-DK-083912, and Vasculitis Clinical Research Consortium (VCRC), U54 AR057319, and U54 RR019497 are part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the Office of Rare Diseases Research (ORDR) and the National Center for the Advancement of Translational Sciences (NCATS), part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), and the National Institute of Diabetes, Digestive, and Kidney Diseases. Additional funding and/or programmatic support for this project has also been provided by the Else Kröner-Fresenius Foundation (ERCB), VCRC, University of Michigan, the NephCure Kidney International and the Halpin Foundation, and the Applied Systems Biology Core at the University of Michigan George M. O'Brien Kidney Translational Core Center.

ERCB members at the time of the study: Clemens David Cohen, Holger Schmid, Michael Fischereider, Lutz Weber, Matthias Kretzler, Detlef Schlöndorff, Munich/Zurich/AnnArbor/New York; Jean Daniel. Sraer, Pierre Ronco, Paris; Maria Pia Rastaldi, Giuseppe D'Amico, Milano; Peter Doran, Hugh Brady, Dublin; Detlev Mönks, Christoph Wanner, Würzburg; Andrew Rees, Aberdeen and Vienna; Frank Strutz, Gerhard Anton Müller, Göttingen; Peter Mertens, Jürgen Floege, Aachen; Norbert Braun, Teut Risler, Tübingen; Loreto Gesualdo, Francesco Paolo Schena, Bari; Gunter Wolf, Jena; Rainer Oberbauer, Donscho Kerjaschki, Vienna; Bernhard Banas, Bernhard Krämer, Regensburg; Moin Saleem, Bristol; Rudolf Wüthrich, Zurich; Walter Samtleben, Munich; Harm Peters, Hans-Hellmut Neumayer, Berlin; Mohamed Daha, Leiden; Katrin Ivens, Bernd Grabensee, Düsseldorf; Francisco Mampaso(+), Madrid; Jun Oh, Franz Schaefer, Martin Zeier, Hermann-Joseph Gröne, Heidelberg; Peter Gross, Dresden; Giancarlo Tonolo, Sassari; Vladimir Tesar, Prague; Harald Rupprecht, Bayreuth; Hermann Pavenstädt, Münster; Hans-Peter Marti, Bern; Peter Mertens, Magdeburg, Jens Gerth, Zwickau.

References

1. Pariser AR, Gahl WA. Important role of translational science in rare disease innovation, discovery, and drug development. *J Gen Intern Med*. 2014;29 Suppl 3:S804-807.
2. Merkel PA, Manion M, Gopal-Srivastava R, et al. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. *Orphanet J Rare Dis*. 2016;11(1):66.
3. Targeted Drug Development: Why Are Many Diseases Lagging Behind? 2015.
4. Groft SC. Rare diseases research: expanding collaborative translational research opportunities. *Chest*. 2013;144(1):16-23.
5. Martini S, Nair V, Keller BJ, et al. Integrative biology identifies shared transcriptional networks in CKD. *J Am Soc Nephrol*. 2014;25(11):2559-2572.
6. Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. *Nat Rev Nephrol*. 2017;13(6):359-367.
7. Catlett NL, Bargnesi AJ, Ungerer S, et al. Reverse causal reasoning: applying qualitative causal knowledge to the interpretation of high-throughput data. *BMC Bioinformatics*. 2013;14:340.
8. Laifenfeld D, Gilchrist A, Drubin D, et al. The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma. *Toxicol Sci*. 2010;113(1):254-266.
9. Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics*. 2014;30(4):523-530.
10. Subramanian A, Narayan R, Corsello SM, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell*. 2017;171(6):1437-1452 e1417.
11. Gillies CE, Putler R, Menon R, et al. An eQTL landscape of kidney tissue in human nephrotic syndrome. *Am J Hum Genet*. 2018;In press.
12. Wen X, Lee Y, Luca F, Pique-Regi R. Efficient Integrative Multi-SNP Association Analysis via Deterministic Approximation of Posteriors. *Am J Hum Genet*. 2016;98(6):1114-1129.
13. Tao J, Mariani L, Eddy S, et al. JAK-STAT signaling is activated in the kidney and peripheral blood cells of patients with focal segmental glomerulosclerosis. *Kidney Int*. 2018;In press.
14. Greene CS, Krishnan A, Wong AK, et al. Understanding multicellular function and disease with human tissue-specific networks. *Nat Genet*. 2015;47(6):569-576.
15. Samarajiwa SA, Forster S, Auchettl K, Hertzog PJ. INTERFEROME: the database of interferon regulated genes. *Nucleic Acids Res*. 2009;37(Database issue):D852-857.
16. Brosius FC, Tuttle KR, Kretzler M. JAK inhibition in the treatment of diabetic kidney disease. *Diabetologia*. 2016;59(8):1624-1627.
17. Ju W, Nair V, Smith S, et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. *Sci Transl Med*. 2015;7(316):316ra193.
18. Facey K, Hansen HP. The imperative for patient-centred research to develop better quality services in rare diseases. *Patient*. 2015;8(1):1-3.
19. Henger A, Kretzler M, Doran P, et al. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. *Kidney Int*. 2004;65(3):904-917.
20. Kusaba T, Lalli M, Kramann R, Kobayashi A, Humphreys BD. Differentiated kidney epithelial cells repair injured proximal tubule. *Proc Natl Acad Sci U S A*. 2014;111(4):1527-1532.
21. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. *Am J Pathol*. 2010;176(1):85-97.
22. Grande MT, Sanchez-Laorden B, Lopez-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. *Nat Med*. 2015;21(9):989-997.
23. Hato T, El-Achkar TM, Dagher PC. Sisters in arms: myeloid and tubular epithelial cells shape renal innate immunity. *Am J Physiol Renal Physiol*. 2013;304(10):F1243-1251.

24. Holtzman MJ, Byers DE, Alexander-Brett J, Wang X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. *Nat Rev Immunol*. 2014;14(10):686-698.
25. Zhou D, Liu Y. Renal fibrosis in 2015: Understanding the mechanisms of kidney fibrosis. *Nat Rev Nephrol*. 2016;12(2):68-70.
26. Knudsen L, Ruppert C, Ochs M. Tissue remodelling in pulmonary fibrosis. *Cell Tissue Res*. 2017;367(3):607-626.
27. Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. *J Am Soc Nephrol*. 2017;28(9):2756-2767.
28. Laurino S, Chaudhry A, Booth A, Conte G, Jayne D. Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. *Nephrol Dial Transplant*. 2010;25(10):3307-3314.
29. Wegener's Granulomatosis Etanercept Trial Research G. Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med*. 2005;352(4):351-361.
30. Joy MS, Gipson DS, Powell L, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. *Am J Kidney Dis*. 2010;55(1):50-60.
31. Wiggins JE, Patel SR, Shedden KA, et al. NFkappaB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. *J Am Soc Nephrol*. 2010;21(4):587-597.
32. Beeken M, Lindenmeyer MT, Blattner SM, et al. Alterations in the ubiquitin proteasome system in persistent but not reversible proteinuric diseases. *J Am Soc Nephrol*. 2014;25(11):2511-2525.
33. Bontscho J, Schreiber A, Manz RA, Schneider W, Luft FC, Kettritz R. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. *J Am Soc Nephrol*. 2011;22(2):336-348.
34. Ponticelli C, Locatelli F. Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls. *Clin J Am Soc Nephrol*. 2018;13(5):815-822.
35. Tuttle KR, Brosius FC, Adler SG, et al. JAK1/JAK2 Inhibition by Baricitinib in Diabetic Kidney Disease: Results from a Phase 2 Randomized Controlled Clinical Trial. *Nephrol. Dial. Transplant*. In press.
36. Zhang H, Nair V, Saha J, et al. Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice. *Kidney Int*. 2017;92(4):909-921.
37. Hodgin JB, Nair V, Zhang H, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. *Diabetes*. 2013;62(1):299-308.
38. Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. *Diabetes*. 2009;58(2):469-477.
39. Kanazawa T, Ichii O, Otsuka S, Namiki Y, Hashimoto Y, Kon Y. Hepatocyte nuclear factor 4 alpha is associated with mesenchymal-epithelial transition in developing kidneys of C57BL/6 mice. *J Vet Med Sci*. 2011;73(5):601-607.
40. Kaminski MM, Tosic J, Kresbach C, et al. Direct reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors. *Nat Cell Biol*. 2016;18(12):1269-1280.
41. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *N Engl J Med*. 2017;376(7):652-662.
42. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. *N Engl J Med*. 2017;377(1):62-70.
43. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm>.
44. Lindenmeyer MT, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. *J Am Soc Nephrol*. 2007;18(6):1765-1776.
45. Gadegbeku CA, Gipson DS, Holzman LB, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. *Kidney Int*. 2013;83(4):749-756.

46. Cohen CD, Frach K, Schlondorff D, Kretzler M. Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. *Kidney Int.* 2002;61(1):133-140.
47. Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. *Nucleic Acids Res.* 2005;33(20):e175.
48. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics.* 2007;8(1):118-127.
49. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci U S A.* 2001;98(9):5116-5121.
50. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res.* 2002;30(1):207-210.
51. Bethunaickan R, Berthier CC, Zhang W, Kretzler M, Davidson A. Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. *PLoS One.* 2013;8(10):e77489.
52. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science.* 2006;313(5795):1929-1935.
53. Rusinova I, Forster S, Yu S, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. *Nucleic Acids Res.* 2013;41(Database issue):D1040-1046.
54. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med.* 2006;145(4):247-254.
55. Barisoni L, Nast CC, Jennette JC, et al. Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE). *Clin J Am Soc Nephrol.* 2013;8(8):1449-1459.
56. Barisoni L, Troost JP, Nast C, et al. Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital images. *Mod Pathol.* 2016;29(7):671-684.

Appendix I: Members of the Nephrotic Syndrome Study Network (NEPTUNE)

NEPTUNE Enrolling Centers

Case Western Reserve University, Cleveland, OH: J Sedor^{*}, K Dell^{**}, M Schachere[#]

Children's Hospital, Los Angeles, CA: K Lemley^{*}, L Whitted[#]

Children's Mercy Hospital, Kansas City, MO: T Srivastava^{*}, C Haney[#]

Cohen Children's Hospital, New Hyde Park, NY: C Sethna^{*}, S Gurusinghe[#]

Columbia University, New York, NY: G Appel^{*}, M Toledo[#]

Emory University, Atlanta, GA: L Greenbaum^{*}, C Wang^{**}, B Lee[#]

Harbor-University of California Los Angeles Medical Center: S Adler^{*}, C Nast^{*†}, J La Page[#]

John H. Stroger Jr. Hospital of Cook County, Chicago, IL: A Athavale^{*}, M Itteera[#]

Johns Hopkins Medicine, Baltimore, MD: A Neu^{*}, S Boynton[#]

Mayo Clinic, Rochester, MN: F Fervenza^{*}, M Hogan^{**}, J Lieske^{*}, V Chernitskiy[#]

Montefiore Medical Center, Bronx, NY: F Kaskel^{*}, N Kumar^{*}, P Flynn[#]

NIDDK Intramural, Bethesda MD: J Kopp^{*}, E Castro-Rubio[#], E Brede[#]

New York University Medical Center, New York, NY: H Trachtman^{*}, O Zhdanova^{**}, F Modersitzki[#], S Vento[#]

Stanford University, Stanford, CA: R Lafayette^{*}, K Mehta[#]

Temple University, Philadelphia, PA: C Gadegbeku^{*}, D Johnstone^{**}, Z Pfeffer[#]

University Health Network Toronto: D Cattarun^{*}, M Hladunewich^{**}, H Reich^{**}, P Ling[#], M Romano[#]

University of Miami, Miami, FL: A Fornoni^{*}, L Barisoni^{*}, C Bidot[#]

University of Michigan, Ann Arbor, MI: M Kretzler^{*}, D Gipson^{*}, A Williams[#], R Pitter[#]

University of North Carolina, Chapel Hill, NC: P Nachman^{*}, K Gibson^{*}, S Grubbs[#], Anne Froment[#]

University of Pennsylvania, Philadelphia, PA: L Holzman^{*}, K Meyers^{**}, K Kallem[#], FJ Cerecino[#]

University of Texas Southwestern, Dallas, TX: K Sambandam^{*}, E Brown^{**}, N Johnson[#]

University of Washington, Seattle, WA: A Jefferson^{*}, S Hingorani^{**}, K Tuttle^{**§}, K Klepach[#], M Kelton[#], A Cooper^{#§}

Wake Forest University, Winston-Salem, NC: B Freedman^{*}, JJ Lin^{**}, M Spainhour[#], S Gray[#]

Data Analysis and Clinical Coordinating Center: M Kretzler, L Barisoni, C Gadegbeku, B Gillespie, D Gipson, L Holzman, L Mariani, M Sampson, P Song, J Troost, J Zee, E Herreshoff, C Kincaid, C Lienczewski, T Mainieri, A Williams

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Program Office: K Abbott, C Roy

The National Center for Advancing Translational Sciences (NCATS) Program Office: T Urv, PJ Brooks

*Principal Investigator; **Co-investigator; #Study Coordinator

†Cedars-Sinai Medical Center, Los Angeles, CA

§Providence Medical Research Center, Spokane, WA

Figure 1. Schematic overview of the analysis approach for the approach identifying inflammatory targets and STAT1 activation in samples from subjects with nephrotic syndrome (NS) and ANCA-associated vasculitis (AAV).

A.

B.

Figure 2. a.) Venn diagram of the number of tubulointerstitial differentially expressed genes (fold change > 1.3 (up- and down-regulated genes), q -value < 0.05) in ANCA-associated vasculitis (AAV) (blue circle) and nephrotic syndrome (NS) (yellow circle). b.) Heatmap representation of the 511 shared transcripts across samples in the dataset including living donors (LD). Expression values were plotted with row normalized Z-score scaling (blue = lower expression, red = higher expression).

Figure 3. A.) Hierarchical clustering (Ward's method) of shared transcripts identified in the tubulointerstitial discovery set on the test data set. B.) Bar chart of histological disease diagnosis, focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and membranous glomerulonephropathy (MN), AAV in each of the four clusters. C.) Box plots with data distribution of eGFR (ml/min/1.72m²) by histological diagnosis and cluster. D.) Correlation of log2 mRNA expression with log2 eGFR of select transcripts enriched in patients within cluster 4: D. *C3*, E. *SERPINA3*, and F. *CXCL6* (right panel) enriched in patients in cluster 4 and correlated with eGFR across the entire cohort.

Figure 4. mRNA expression profile of C3 from samples from LD, and NS and AAV in the: A.) tubulointerstitium from the discovery cohort, B.) glomeruli from the discovery cohort, C.) tubulointerstitium from the validation cohort, D.) glomeruli from the validation cohort. E.) Complement system pathway diagram indicating the genes in the complement pathway up-regulated (colored red) in the tubulointerstitium of diseased samples in both the discovery and validation cohort.

Figure 5. A.) Inflammatory mechanistic network from IPA upstream regulator analysis. B.) Bar chart indicating the number of compounds in the indicated compound classes with CMap profile scores ranging from -50 to -100. C.) Waterfall plot of CMap profile scores by knockdown experiments, with the STAT1 knockdown experiment indicated.

Figure 6. Kaplan-Meier analysis of tubulointerstitial *STAT1* expression and its association with outcome in the NEPTUNE cohort.

Figure 7. Association of STAT1 activation scores with biomarkers and clinical data. Correlation of the STAT1 activation score with *CXCL10* mRNA in the A.) Discovery cohort and B.) Validation cohort, with C.) interstitial fibrosis from the NEPTUNE cohort, with *EGF* mRNA in the D.) Discovery cohort and E.) Validation cohort, and with F.) urinary EGF from the NEPTUNE cohort.

Discovery cohort	Nephrotic syndrome	ANCA-associated vasculitis	Living donor
Glom samples	58	22	21
TI samples	47	21	21
eGFR, MDRD (ml/min/1.73m ²)	83 ± 39	46 ± 31	104 ± 31
Age	47.2 ± 17.7	58.0 ± 13.8	47.3 ± 11.5
Sex (%Female)	45	43	45
Validation Cohort			
Glom samples	90	15	6
TI samples	107	57	5
eGFR, MDRD (ml/min/1.73m ²)	77 ± 32	31 ± 27	108 ± 33
Age	47.1 ± 15.7	57.8 ± 9.8	52.5 ± 6.9
Sex (%Female)	33	58	57

Table 1. Demographic information of subjects profiled in the discovery and validation cohorts. Age and eGFR are reported as mean ± standard deviation.

Gene Symbol	Entrez GeneID	AAV vs. LD log2 fold-change	AAV vs. LD q-value	NS vs LD log2 fold-change	NS vs LD q-value
LTF	4057	4.73	<0.0001	3.59	<0.0001
CXCL6	6372	2.92	<0.0001	2.81	<0.0001
LYZ	4069	3.13	<0.0001	2.15	<0.0001
REG1A	5967	2.87	<0.0001	2.25	<0.0001
OLFM4	10562	2.77	<0.0001	1.71	5.4E-3
NNMT	4837	2.91	<0.0001	1.38	2.2E-4
SERPINA3	12	2.94	<0.0001	1.33	<0.0001
C3	718	2.72	<0.0001	1.48	<0.0001
PDK4	5166	-1.97	<0.0001	-2.12	<0.0001
MMP7	4316	2.47	<0.0001	1.56	3.4E-4

Table 2. Top 10 differentially expressed genes sorted by the average absolute fold change across both AAV and NS relative to living donors.

Discovery cohort	TI	Glom
AAV DE genes	1768	2322
NS DE genes	565	1059
Common DE genes (AAV + NS)	511	928
Validation cohort		
Common DE genes present in validation cohort	508	928
Common DE genes (AAV + NS) $q < 0.05$	308/508 (60%)	592/928 (64%)
Common DE genes (AAV + NS) $q < 0.1$	396/508 (77%)	609/928 (66%)

Table 3. Summary level information for shared gene expression profiles in the glomeruli and tubulointerstitium from the discovery and validation cohorts. In the discovery cohort, differentially expressed (DE) genes were defined as those with $|FC| > 1.3$ and $q\text{-value} < 0.05$.

Compartment	Canonical Pathway	Source	Enrichment p-value
TI	Complement System	IPA Canonical Pathways	9.68E-7
TI	Classical Complement Pathway	GGA	3.48E-4
TI	Alternative Complement Pathway	GGA	1.73E-2
Glomeruli	Complement System	IPA Canonical Pathways	4.38E-6
Glomeruli	Classical Complement Pathway	GGA	6.50E-3
Glomeruli	Alternative Complement Pathway	GGA	2.65E-2

Table 4. Significant enrichment of complement pathways in IPA and Genomatix Genome Analyzer from the 396 and 609 shared and validated transcripts in the TI and glomeruli, respectively.

Upstream Regulator	Molecule Type	Predicted Activation State	Activation z-score	p-value of overlap
IFNG	cytokine	Activated	4.32	4.23E-34
TNF	cytokine	Activated	2.94	2.42E-32
NR3C1	ligand-dependent nuclear receptor	Inhibited	-2.69	1.80E-16
OSM	cytokine	Activated	2.81	4.16E-16
PDGF BB	complex	Inhibited	-3.56	1.08E-15
Vegf	group	Inhibited	-2.29	5.66E-14
CREB1	transcription regulator	Inhibited	-2.26	2.97E-13
MAPK1	kinase	Inhibited	-3.39	1.15E-12
IL1	group	Activated	2.11	1.52E-12
IRF1	transcription regulator	Activated	3.39	3.86E-12
Pkc(s)	group	Inhibited	-2.11	9.64E-12
STAT1	transcription regulator	Activated	3.62	2.90E-11
FSH	complex	Inhibited	-2.44	8.75E-11
Interferon alpha	group	Activated	4.21	9.89E-11
IL27	cytokine	Activated	3.39	1.63E-10

Table 5. Ingenuity Pathways Analysis Results for the top 15 biological network nodes (by p-value enrichment) with a prediction of activated or inhibited based on underlying gene expression profiles.

Node Name	Description	IPA Z-score	CMap Profile Score	CMap Profile ID	CMap experiment type	Consensus
STAT1	SH2 domain containing	3.621	-75.82	CGS001-6772	kd	✓
CD44	CD molecules	3.005	-66.27	CGS001-960	kd	✓
	SRY (sex determining region Y)- boxes					✓
SOX2	boxes	2.093	-61.3	CGS001-6657	kd	
FOXA1	Forkhead boxes	-2.126	70.14	CGS001-3169	kd	✓
thapsigargin	ATPase inhibitor	-2.319	-50.62	BRD-K69023402	cp	✓
thapsigargin	ATPase inhibitor	-2.319	-71.76	BRD-A62809825	cp	✓
IPMK	-	-2.401	51.12	CGS001-253430	kd	✓
HNF4A	Hepatocyte nuclear factor-4 receptors	-2.418	-90	ccsbBroad304_00763	oe	✓
fluticasone	Glucocorticoid receptor agonist	-2.758	-71.5	BRD-K14791739	cp	✓
fluticasone	Glucocorticoid receptor agonist	-2.758	-73.91	BRD-A59943784	cp	✓
fluticasone	Glucocorticoid receptor agonist	-2.758	-82.83	BRD-K62310379	cp	✓
anisomycin	DNA synthesis inhibitor	-2.945	-98.51	BRD-K91370081	cp	✓
MAPK1	MAPK:ERK subfamily	-3.387	57.55	CGS001-5594	kd	✓
dexamethasone	Glucocorticoid receptor agonist	-5.019	-60.74	BRD-A93424738	cp	✓
dexamethasone	Glucocorticoid receptor agonist	-5.019	-88.45	BRD-A35108200	cp	✓
dexamethasone	Glucocorticoid receptor agonist	-5.019	-95.14	BRD-K47635719	cp	✓
TGM2	Transglutaminases	2.138	94.73	CGS001-7052	kd	x
CAT	-	-2.18	-56.81	CGS001-847	kd	x
troglitazone	Insulin sensitizer	-2.268	50.43	BRD-A13084692	cp	x
	Homeoboxes / ANTP class : HOXL					
PDX1	subclass	-2.357	-83.13	CGS001-3651	kd	x
ELK1	ETS Transcription Factors	-2.367	-63.63	CGS001-2002	kd	x

Table 6. IPA nodes with corresponding profile scores from CMap and LINCS database (CLUE) using the shared TI transcriptional profile.